Caris Life Sciences, Inc. (CAI): R&D Expense
$101.58M
Year ended 2025-12-31
$117.14M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $101.58M | -10.8% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $113.92M | -2.5% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $116.88M | n/a | 2026-03-03, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $101.58M | -10.8% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $364.19M | +4.7% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $70.81M | +2.2% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $71.43M | -1.5% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $51.85M | -0.4% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $53.91M | +10.4% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $49.38M | +34.9% |
| Natera, Inc. (NTRA) | 2025-12-31 | $624.11M | +54.4% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $195.79M | -39.3% |
Compare CAI, GH, VCYT, CDNA side by side · Screen every company in Services-Medical Laboratories ↗